Targeted Therapy

Targeted Therapy

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line treatment for a patient with advanced non squamous non small cell lung cancer, high PD-L1, and no driver mutation.
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal approach for a fit patient with advanced squamous NSCLC and low tumor PD-L1 expression.
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the treatment choice between targeted therapy and immunotherapy in a patient with an EGFR Mutation and high PDL-1.
Cancer Journey:
Cancer Type:
,
,
,
,
The Global Resource for Advancing Cancer Education (GRACE), in partnership with Georgetown University Hospital is pleased to present the videos from the panel discussion "2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know".
Cancer Journey:
Cancer Type:

Articles

The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
Cancer Journey:
Cancer Type:
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce James Stevenson, MD.
Cancer Journey:
Cancer Type:
Disease Learning:
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
Cancer Journey:
Cancer Type:
Amidst all of the glowing reports about immunotherapy for lung and many other cancers, it would be understandable for patients and physicians to be tempted to rush toward prioritizing immunotherapy as the first treatment strategy to pursue. In fact ...
Cancer Journey:
Cancer Type:
Among the many novel concepts in managing immunotherapy is the potential for “pseudo-progression”. This unusual phenomenon is when a patient’s scans...
Cancer Journey:
Cancer Type:

Community Forum

Progression after 3 1/2 years on Tarceva. Tissue biopsy showed T790m negative. Any suggestions/experience on next steps? Onc suggesting I move to Afatinib or a Opdivo. PDL1 was tested and is <1%.
Cancer Journey:
Cancer Type:
Has anyone any information on obtaining and using Vaxira, the Cuban drug, for stage 4 advanced NSCLC? Not sure if US citizens can still travel to...
Cancer Journey:
Cancer Type:
My wife has come a long way with Stage IV lung cancer since 2010. She has now developed acquired resistance to Tarceva. Gene sequence of biopsy from...
Cancer Type: